Associated Papers
POLE/POLD1 mutation in non-exonuclease domain matters for predicting efficacy of immune-checkpoint-inhibitor therapy.
Chen YX et al.
Clinical and Translational Medicine, 2021
34586735 (PubMed )
Supplement: CTM2-11-e524-s001.xlsx › Supplementary_Table_6
Role of POLE and POLD1 in familial cancer.
Mur P et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2020
32792570 (PubMed )
Supplement: 41436_2020_922_MOESM8_ESM.xlsx › Suppl._Table_12
Frequent FOXA1-Activating Mutations in Extramammary Paget's Disease.
Takeichi T et al.
Cancers, 2020
32235312 (PubMed )
Supplement: cancers-12-00820-s001.pdf
Six years' experience with LipidSeq: clinical and research learnings from a hybrid, targeted sequencing panel for dyslipidemias.
Dron JS et al.
Bmc Medical Genomics, 2020
32041611 (PubMed )
Supplement: 12920_2020_669_MOESM1_ESM.xlsx › Supp_Table_4
Select a paper to view details